Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML
This phase II trial studies how well early discharge and outpatient care works in patients with myelodysplastic syndrome or acute myeloid leukemia previously treated with intensive chemotherapy. Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help doctors learn more about the safety of allowing patients to leave the hospital early, the patient's quality of life, use of medical services, and the cost of these services associated with such a policy.
PRIMARY OBJECTIVES: I. Estimate the early death rate in patients discharged after completion of intensive induction or salvage chemotherapy. SECONDARY OBJECTIVES: I. Compare the costs incurred by patients discharged early after induction or salvage chemotherapy with similar patients who are discharged only after their blood counts recover. II. Compare resource utilization (transfusions, etc.) in patients discharged early after induction or salvage chemotherapy with similar patients who are discharged only after blood count recovery. III. Compare the quality of life in patients discharged early after induction or salvage chemotherapy with similar patients who are discharged only after their blood counts recover. OUTLINE: Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a registered nurse (RN), physician assistant (PA), or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days. After completion of study, patients are followed up for 1 month.
Proportion of early deaths among patients who are discharged after completion of induction or salvage chemotherapy
Adult Acute Megakaryoblastic Leukemia (M7)
standard follow-up care
Study Arms / Comparison Groups
Health services research (early discharge, outpatient care)
Description: Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - Diagnosis of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12), (promyelocytic leukemia [PML]/retinoic acid receptor [RAR]), or variants according to the 2008 World Health Organization (WHO) classification - Currently undergoing AML-like intensive induction or re-induction chemotherapy, or is planned to start such therapy within 1 week - Provide signed written informed consent - Patients can be repeatedly enrolled in this protocol (e.g. for induction and 1st or subsequent salvage therapy) Exclusion Criteria: - Drug hypersensitivities or allergies disabling use of prophylactic antimicrobials
18 Years - 75 Years
Accepts Healthy Volunteers
Roland Walter, ,
Fred Hutchinson Cancer Center
Roland Walter, Principal Investigator, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium